The 100 Lowest Beta Stocks In The S&P 500 Sure Dividend

Sure Dividend

High-Quality Dividend Stocks, Long-Term Plan
The Sure Dividend Investing MethodMember's Area

The 100 Lowest Beta Stocks In The S&P 500

Updated on January 21st, 2021 by Bob Ciura

In the world of investing, volatility matters. Investors are reminded of this every time there is a downturn in the broader market and individual stocks that are more volatile than others experience enormous swings in price.

Volatility is a proxy for risk; more volatility generally means a riskier portfolio. The volatility of a security or portfolio against a benchmark is called Beta.

In short, Beta is measured via a formula that calculates the price risk of a security or portfolio against a benchmark, which is typically the broader market as measured by the S&P 500.

Here’s how to read stock betas:

Interestingly, low beta stocks have historically outperformed the market… But more on that later.

You can download a spreadsheet of the 100 lowest beta stocks (along with important financial metrics like price-to-earnings ratios and dividend yields) below:


This article will discuss beta more thoroughly, why low-beta stocks tend to outperform, and provide a discussion of the 5 lowest-beta stocks in the Sure Analysis Research Database. The table of contents below allows for easy navigation.

Table of Contents

The Evidence for Low Beta Outperformance

Beta is helpful in understanding the overall price risk level for investors during market downturns in particular. The lower the Beta value, the less volatility the stock or portfolio should exhibit against the benchmark. This is beneficial for investors for obvious reasons, particularly those that are close to or already in retirement, as drawdowns should be relatively limited against the benchmark.

Importantly, low or high Beta simply measures the size of the moves a security makes; it does not mean necessarily that the price of the security stays nearly constant. Indeed, securities can be low Beta and still be caught in long-term downtrends, so this is simply one more tool investors can use when building a portfolio.

The conventional wisdom would suggest that lower Beta stocks should underperform the broader markets during uptrends and outperform during downtrends, offering investors lower prospective returns in exchange for lower risk.

However, history would suggest that simply isn’t the case. Indeed, this paper from Harvard Business School suggests that not only do low Beta stocks not underperform the broader market over time – including all market conditions – they actually outperform.

A long-term study wherein the stocks with the lowest 30% of Beta scores in the US were pitted against stocks with the highest 30% of Beta scores suggested that low Beta stocks outperform by several percentage points annually.

Over time, this sort of outperformance can mean the difference between a comfortable retirement and having to continue working. While low Beta stocks aren’t a panacea, the case for their outperformance over time – and with lower risk – is quite compelling.

How To Calculate Beta

The formula to calculate a security’s Beta is fairly straightforward. The result, expressed as a number, shows the security’s tendency to move with the benchmark.

For example, a Beta value of 1.0 means that the security in question should move in lockstep with the benchmark. A Beta of 2.0 means that moves in the security should be twice as large in magnitude as the benchmark and in the same direction, while a negative Beta means that movements in the security and benchmark tend to move in opposite directions or are negatively correlated.

In other words, negatively correlated securities would be expected to rise when the overall market falls, or vice versa. A small value of Beta (something less than 1.0) indicates a stock that moves in the same direction as the benchmark, but with smaller relative changes.

Here’s a look at the formula:

Beta Formula

The numerator is the covariance of the asset in question with the market, while the denominator is the variance of the market. These complicated-sounding variables aren’t actually that difficult to compute – especially in Excel.

Additionally, Beta can also be calculated as the correlation coefficient of the security in question and the market, multiplied by the security’s standard deviation divided by the market’s standard deviation.

Finally, there’s a greatly simplified way to calculate Beta by manipulating the capital asset pricing model formula (more on Beta and the capital asset pricing model later in this article).

Here’s an example of the data you’ll need to calculate Beta:

To show how to use these variables to do the calculation of Beta, we’ll assume a risk-free rate of 2%, our stock’s rate of return of 7% and the benchmark’s rate of return of 8%.

You start by subtracting the risk-free rate of return from both the security in question and the benchmark. In this case, our asset’s rate of return net of the risk-free rate would be 5% (7% – 2%). The same calculation for the benchmark would yield 6% (8% – 2%).

These two numbers – 5% and 6%, respectively – are the numerator and denominator for the Beta formula. Five divided by six yields a value of 0.83, and that is the Beta for this hypothetical security. On average, we’d expect an asset with this Beta value to be 83% as volatile as the benchmark.

Thinking about it another way, this asset should be about 17% less volatile than the benchmark while still having its expected returns correlated in the same direction.

Beta & The Capital Asset Pricing Model (CAPM)

The Capital Asset Pricing Model, or CAPM, is a common investing formula that utilizes the Beta calculation to account for the time value of money as well as the risk-adjusted returns expected for a particular asset.

Beta is an essential component of the CAPM because without it, riskier securities would appear more favorable to prospective investors as their risk wouldn’t be accounted for in the calculation.

The CAPM formula is as follows:

CAPM Formula

The variables are defined as:

The risk-free rate is the same as in the Beta formula, while the Beta that you’ve already calculated is simply placed into the CAPM formula. The expected return of the market (or benchmark) is placed into the parentheses with the market risk premium, which is also from the Beta formula. This is the expected benchmark’s return minus the risk-free rate.

To continue our example, here is how the CAPM actually works:

ER = 2% + 0.83(8% – 2%)

In this case, our security has an expected return of 6.98% against an expected benchmark return of 8%. That may be okay depending upon the investor’s goals as the security in question should experience less volatility than the market thanks to its Beta of less than 1. While the CAPM certainly isn’t perfect, it is relatively easy to calculate and gives investors a means of comparison between two investment alternatives.

Now, we’ll take a look at five stocks that not only offer investors low Beta scores, but attractive prospective returns as well.

Analysis On The 5 Lowest-Beta Stocks

The following 5 stocks have the lowest (but positive) Beta values, in ascending order from lowest to highest. We focused on Betas above 0, as we are still looking for stocks that are positively correlated with the broader market:

5. Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb was created when Bristol-Myers and Squibb merged in 1989, but Bristol-Myers can trace its corporate beginnings back to 1887. Today this leading drug maker of cardiovascular and anti-cancer therapeutics has annual revenues of about $42 billion.

In the 2020 third quarter, BMY’s adjusted earnings-per-share increased 39% from the same quarter a year ago. Revenue soared 76%, largely the result of the Celgene acquisition. Pro-forma revenue increased 6%, indicating organic growth as well.

Source: Investor Presentation

BMY has positive growth potential moving forward. Not only is the Celgene acquisition an immediate catalyst, the company’s strong pharmaceutical pipeline will fuel its future growth. Eliquis, which prevents blood clots, grew sales by 9% last quarter as demand remains high in the United States. Separately, revenue increased 8% for Orencia, which treats rheumatoid arthritis.

BMY has a 5-year Beta score of 0.63.

Click here to see our Sure Analysis Research Database report on Bristol-Myers Squibb.

4. Costco Wholesale (COST)

Costco is a diversified warehouse retailer that operates about 800 warehouses that collectively generate about $170 billion in annual sales. Costco reported fiscal first-quarter earnings on December 10th, 2020 with results coming in well ahead of expectations on both the top and bottom lines once again. Total revenue was up nearly 17% year-over-year to $43.2 billion, driven once again by very strong demand at its warehouses, as well as rising membership revenues.

Adjusted comparable sales soared 17% year-over-year for the consolidated company, with all three of the company’s geographic segments reporting comparable sales gains of at least 16.8%. In addition, Costco’s once-small e-commerce business saw 86% comparable growth from the same period last year as Costco continues to add digital capabilities.

Net income came to $1.17 billion, or $2.62 per diluted share. These were up from $844 million and $1.90 per diluted share, respectively, in the year-ago period. The company did see a tax benefit of $145 million in Q1, which amounted to 33 cents per share..

Costco has a 5-year Beta score of 0.60.

Click here to see our Sure Analysis Research Database report on Costco.

3. Becton, Dickinson & Company (BDX)

Becton, Dickinson & Company is a global leader in the medical supply industry. The company was founded in 1897 and has almost 50,000 employees across 190 countries. Becton, Dickinson & Company is on the exclusive list of Dividend Aristocrats. You can see all 65 Dividend Aristocrats here.

BD has been very active on the acquisition front in recent years. BD completed its $24 billion purchase of C.R. Bard at the end of 2017. After the Bard acquisition, BD is now composed of three segments. Products sold by the Medical Division include needles for drug delivery systems,and surgical blades. The Life Sciences division provides products for the collection and transportation of diagnostic specimens. The Intervention segment includes several of the products produced by Bard.

On 11/5/2020, BDX released earnings results for the fourth quarter of fiscal 2020. Revenue increased 4.4% to $4.8 billion, $300 million better than expected. Adjusted earnings-per-share of $2.79 was a 15.7% decrease from the prior year, but $0.25 above estimates. For the fiscal year, revenue declined 1% to $17.1 billion. Adjusted EPS of $10.19 was 12.8% lower than the prior year, but $0.29 above the midpoint of the company’s guidance.

BDX has a 5-year Beta of 0.57.

Click here to see our Sure Analysis Research Database report on BDX.

2. Walmart Inc. (WMT)

Walmart traces its roots back to 1945 when Sam Walton opened his first discount store. The company has since grown into the largest retailer in the world, serving nearly 300 million customers each week. Revenue will be in excess of $500 billion this year.

Related: For Sure Dividend’s analysis of the 6 major grocery store stocks, click here.

Walmart reported third-quarter earnings on November 17th, 2020 with results coming in ahead of expectations on the top and bottom lines once again. The company said that strength across a variety of different consumer staple and discretionary categories led to total revenue of $135 billion, up 5.2% year-over-year.

Excluding currency changes, total revenue would have been 6.1% higher. US comparable sales for the Walmart brand were up 6.4% year-over-year on broad-based strength. Walmart US’ digital sales soared 79% year-over-year and was responsible for 5.7% of the 6.4% comparable sales increase in Q3.

Operating income was $5.8 billion, a 22.5% increase year-over-year. Adjusted earnings-per-share was $1.34, up from $1.16 in the year-ago period.

Walmart has a 5-year Beta of 0.52.

Click here to see our Sure Analysis Research Database report on Walmart.

1. Gilead Sciences (GILD)

Gilead Sciences is a biotechnology company that operates with a clear focus on antiviral medication and treatments. Its main products include treatments for HIV, Hepatitis B, and Hepatitis C (HBV/HCV), but Gilead has also ventured into other areas such as oncology. Gilead is a large-cap stock with a market cap above $80 billion.

The company performed relatively well to start 2020, given the extremely weak global economy due to the coronavirus pandemic. Gilead Sciences reported its third-quarter earnings results on October 28. The company generated revenues of $6.6 billion during the quarter, which was above the analyst consensus estimate. The company’s top line grew by 17% compared to the previous year’s quarter. Gilead’s Hepatitis C franchise continued to shrink, due to a declining patient pool for this indication.

Gilead’s other businesses showed a stronger performance, but the most meaningful growth driver was Gilead’s COVID therapy Vecluvy (remdesivir), which generated revenues of $870 million during the quarter. Bictarvy, Gilead’s biggest drug in terms of sales volumes, grew by 50% during the quarter, although that was offset by some declines in other HIV therapies that were, to some extent, replaced by Bictarvy. Gilead generated earnings-per-share of $2.11during the third quarter, which was above the consensus estimate.

Gilead has a 5-year Beta of 0.49.

Click here to see our Sure Analysis Research Database report on Gilead.

Final Thoughts

Investors must take risk into account when selecting from prospective investments. After all, if two securities are otherwise similar in terms of expected returns but one offers a much lower Beta, the investor would do well to select the low Beta security as they may offer better risk-adjusted returns.

Using Beta can help investors determine which securities will produce more volatility than the broader market and which ones may help diversify a portfolio, such as the ones listed here.

The five stocks we’ve looked at not only offer low Beta scores, but they also offer attractive dividend yields. Sifting through the immense number of stocks available for purchase to investors using criteria like these can help investors find the best stocks to suit their needs.

Thanks for reading this article. Please send any feedback, corrections, or questions to

More from sure dividend
The Sure Dividend Investing MethodMember's Area